AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00304187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin
Description: Erythromycin, 250 mg or 500 mg, three times a day for 6 weeks
Study NCT02372123 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: lifestyle advice
Description: Investigators will give lifestyle advice to patients such as exercising regularly, limiting caffeine, sugar and alcohol intake, reduction or cessation of smoking
Study NCT02725788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New PIV Dressing
Description: A commercially available breathable, transparent film dressing with a soft-cloth border, notch and securement tape strip. The dressing system is used in the study to cover a peripheral intravenous catheter insertion site and secure the catheter. Dressing system is to remain in place until the PIV catheter is discontinued which is anticipated to be 72 hours. The dressing and PIV site will be observed daily. If dressing excessively lifts from the skin, the dressing system will be replaced with the same, assigned dressing system. The number of dressing replacements and the duration of wear will be measured while the same study PIV catheter dwells, an average of 72 hours during the subject's hospitalization.
Study NCT02725788 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Standard PIV Dressing
Description: A commercially available breathable, transparent film dressing used with a one inch width piece of Transpore™ medical tape. The dressing system is used in the study to cover a peripheral intravenous catheter insertion site and secure the catheter. Dressing system is to remain in place until catheter is discontinued which is anticipated to be 72 hours. The dressing and PIV site will be observed daily. If dressing excessively lifts from the skin, the dressing system will be replaced with the same, assigned dressing system. The number of dressing replacements and the duration of wear will be measured while the same study PIV catheter dwells, an average of 72 hours during the subject's hospitalization.
Study NCT02372123 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lifestyle advice
Description: Investigators will give lifestyle advice to patients such as exercising regularly, limiting caffeine, sugar and alcohol intake, reduction or cessation of smoking
Study NCT01756001 — intervention group
Intervention type: BEHAVIORAL
Intervention: Paid for adherence
Study NCT03981029 — intervention group
Intervention type: OTHER
Intervention: 4.0mg Folic Acid received through participation in FACT (NCT01355159)
Description: Participants in this study received either daily high-dose folic acid supplementation during pregnancy OR placebo through their participation in FACT (NCT01355159). Details of the FACT Folic Acid intervention are provided below:~Folic Acid 1.0 mg x 4 tablets will be taken daily by oral administration. The majority of women in the study will routinely take 1.0 mg folic acid in a prenatal vitamin supplement, as recommended by their primary obstetrical provider; the study requirements do not require that participants change their practice. Therefore the actual total daily dose may be up to 5.1 mg of folic acid
Study NCT02372123 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: connective tissue manipulation
Description: Investigators will apply connective tissue manipulation on lumbosacral, lower thoracic, and anterior pelvic regions starting from the estimated time of ovulation until the next period begins
Study NCT04453670 — intervention group
Intervention type: PROCEDURE
Intervention: autopsy
Description: autopsy
Study NCT00778414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-Clavulanic acid 600mg - 42.9 mg/ 5 mL oral suspension
Study NCT00778414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-Clavulanic acid 600mg - 42.9 mg/ 5 mL oral suspension
Study NCT03115970 — intervention group
Intervention type: PROCEDURE
Intervention: capillary and venous lactate level measurement
Description: capillary and venous lactate level measurement
Study NCT02730130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study NCT00304187 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 250 mg or 500 mg, three times a day for 6 weeks
Study NCT03981029 — intervention group
Intervention type: OTHER
Intervention: Placebo received through participation in FACT
Description: Participants in this study received either daily high-dose folic acid supplementation during pregnancy OR placebo through their participation in FACT (NCT01355159). Details of the FACT Folic Acid placebo are provided below:~Placebo x 4 tablets will be taken daily by oral administration.
Study NCT04681326 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biological prosthesis
Description: retro-muscular positioning of a swine dermal collagen prosthesis
Study NCT03982667 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PCT-guided group
Description: In the PCT-guided group, the study protocol encourages to stop the prescribed antibiotics if PCT concentration decrease by 80% or more of its peak value (or if PCT concentration is ≥0·25 and \<0·5 μg/L), and strongly encourage to stop the prescribed antibiotics when it reaches a value of \< 0·25 μg/L. The attending physician is free to decide whether to continue antibiotic treatment in patients who reach these thresholds. Reasons for non-adherence will be recorded. Antibiotics in the standard-of-care group will be stopped according to local or national guidelines and according to the discretion of attending physicians. Patients will be followed-up until hospital discharge.
Study NCT02730130 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study NCT05390554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Buteyko Breathing Technique
Description: * The child was instructed to sit and take a relaxed posture in a vertical chair, relax his shoulders and lean his lower back against the back of the chair.~* Until conducting CP, the child was told to avoid alternate breathing, the child was asked to take a small breath in (two seconds), a small breath out (three seconds) and clutch the nose with empty lungs but not too clear on the 'out-breath. To prevent air from escaping through the airways, clutching the nose is necessary.~* The researcher estimates how many seconds the child can continue safely before the need to breathe in again,~* The child was told to hold their breath until the first need to breathe in was felt. Release the nose then and naturally breathe through it smoothly.~* The first intake of breath after the CP should be no higher than the breath before taking the measurement; the child should not hold the breath for too long as this could lead the child to take a major breath after measuring the CP.
Study NCT02113657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 3 mg/kg by vein once every 3 weeks for a total of 4 doses.
Study NCT03250741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rotigotine transdermal patch
Description: Rotigotine transdermal patches 4mg/24hr
Study NCT03250741 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo transdermal patches of the same size as for Rotigotine transdermal patches
Study NCT00729001 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Rotavirus Vaccine - two different formulations
Description: Two oral doses
Study NCT03399812 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Animal protein
Description: The animal protein intervention is a smoothie containing 40 grams of whey protein isolate.
Study NCT03399812 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plant protein
Description: The animal protein intervention is a smoothie containing 40 grams of pea protein isolate.
Study NCT01067833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K201 Tablet
Description: oral tablet, x28 days
Study NCT01067833 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: oral tablet, x28 days
Study NCT03506386 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: As it was an observational study, no intervention was administered.
Study NCT06629168 — intervention group
Intervention type: PROCEDURE
Intervention: Ventriculo-peritoneal shunt placement
Description: Surgical procedure based on implantation a thin catheter into brain lateral ventricle (placed through a burrhole from Kocher point) and connection to prechamber and valve (placed behind the ear under skin) and similar thin catheter pushed under skin of neck, chest and abdomen (where put intraperitoneally). Telemetric prechamber placement according the randomization (www.randomization.com) and the envelope method of choosing of patients.
Study NCT06629168 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Follow-up control #1
Description: Patients after VP shunt placement are assesed in gait, general condition and mini-mental state examination score 3 month after surgery. Brain CT control.
Study NCT06629168 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Follow-up control #2
Description: Patients after VP shunt placement are assesed in gait, general condition and mini-mental state examination score 6 month after surgery. Brain CT control.
Study NCT06629168 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Follow-up control #3
Description: Patients after VP shunt placement are assesed in gait, general condition and mini-mental state examination score 9 months after surgery. Brain CT control.
Study NCT06629168 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Follow-up control #4
Description: Patients after VP shunt placement are assesed in gait, general condition and mini-mental state examination score a month after surgery. Brain CT control, 10-meter-walking test, MMSE, self-assessment.
Study NCT06629168 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Telemetric prechamber reading
Description: Non-invasive reading of telemetric prechamber made during each follow-up control.
Study NCT06629168 — intervention group
Intervention type: OTHER
Intervention: Valve setting change
Description: Changing of valve setting according patient's actual condition. Decission based on clinical state, radiological finding on CT and values readed from telemetric prechamber. Timing - each follow-up control.
Study NCT01316107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: oral
Study NCT01316107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nateglinide
Description: oral
Study NCT04328480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: The colchicine dosage schedule will vary according to the following scenarios:~1. In patients not receiving Lopinavir/Ritonavir~   * Loading dose of 1.5 mg followed by 0.5 mg after two hours (day 1)~  * The next day 0.5 mg bid for 14 days or until discharge.~2. In patients receiving Lopinavir/Ritonavir~   * Loading dose of 0.5 mg (day 1)~  * After 72 hours from the loading dose, 0.5 mg every 72 hours for 14 days or until discharge.~3. Patients under treatment with Colchicine that are starting with Lopinavir/Ritonavir~   * Dose of 0.5 mg 72 hours after starting Lopinavir/Ritonavir.~  * Continue with 0.5 mg every 72 hours for 14 days or until discharge.~Only the oral route will be used except in the case of patients associated with mechanical ventilation or with contraindications to the oral route, in whom it will be administered by nasogastric tube.
Study NCT00729001 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar
Description: Three-dose intramuscular injection (US subjects only)
Study NCT04328480 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Local standard of care
Description: Local standard of care for COVID-19 SARS moderate /high-risk patients
Study NCT00729001 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Prevnar
Description: Three-dose intramuscular injection (US subjects only)
Study NCT04328480 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Local standard of care
Description: Local standard of care for COVID-19 SARS moderate /high-risk patients
Study NCT01217775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH80
Description: PH80 intranasal spray 800 nanograms
Study NCT01217775 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intranasal spray
Description: Placebo intranasal spray
Study NCT00783640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactic Acid
Description: Drug: Lactic Acid (Dermacyd Femina)
Study NCT00187083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan, dexamethasone, vincristine
Description: See Detailed Description section for details of treatment interventions.
Study NCT00187083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E. coli Asparaginase, PEG-L-asparaginase
Description: See Detailed Description section for details of treatment interventions.
Study NCT00187083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erwinia asparaginase
Description: See Detailed Description section for details of treatment interventions.
Study NCT00187083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine, methotrexate, mercaptopurine
Description: See Detailed Description section for details of treatment interventions.
Study NCT00187083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin, etoposide, cytarbine, teniposide
Description: See Detailed Description section for details of treatment interventions.
Study NCT00187083 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chemotherapy, intrathecal chemotherapy, steroid therapy
Description: See Detailed Description section for details of treatment interventions.
Study NCT03038022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGL-3196
Description: Oral
Study NCT03038022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT02573116 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: scaling and root planing
Description: full-mouth intensive removal of subgingival dental plaque biofilms with the use of scaling and root planing after the administration of local anesthesia
Study NCT01783834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib
Description: compare progression free survivla rate and safety to both drugs
Study NCT01783834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: compare PFS rate, safety to both drugs
Study NCT03976089 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recipe 4 Success
Description: The Recipe 4 Success intervention consisted of 10 weekly lessons in which parents and toddlers prepared simple snacks or meals.~All Recipe 4 Success lessons started and ended with some evidence-based information for the parents about children's self-regulation skills or healthy eating habits. Most of each lesson in Recipe 4 Success was devoted to the snack or meal preparation activities. Each week, home visitors coached the parents as they worked with their toddlers to make increasingly challenging snacks and meals. During these activities, home visitors pointed out opportunities for parents to practice sensitive scaffolding strategies. At the same time, these meal and snack preparation activities allowed children to practice multiple age-appropriate self-regulation skills.
Study NCT03976089 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual Early Head Start
Description: Treatment as Usual Early Head Start consisted of an evidence-based curriculum (usually Parents as Teachers) in which home visitors and parents worked with children on activities to support their physical, cognitive, and social-emotional development.
Study NCT04295187 — intervention group
Intervention type: OTHER
Intervention: Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3
Description: Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
Study NCT04295187 — intervention group
Intervention type: OTHER
Intervention: Physical development and General Health
Description: Physical development and General health examination
Study NCT01823263 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Portion Size Task
Description: Participants are given a computer program that gives them the opportunity to choose the portions of a variety of food items that they would ideally like to consume
Study NCT01823263 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: In the morning following partial sleep deprivation or normal sleep, a blood sample will be taken to assess the level of metabolism-linked and neurodegenerative-linked molecules, as well as to assay blood serum and plasma for the presence of hormones involved in hunger such as ghrelin
Study NCT01823263 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interference task
Description: 30-minute interference task
Study NCT01823263 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory tasks
Description: Participants will be allowed to learn a procedural memory task before going to bed. Participants will be retested in the morning to assess their change in performance. Other memory tests will also be given to assess the working memory performance in the morning following the intervention.
Study NCT04295187 — intervention group
Intervention type: OTHER
Intervention: Developmental Red flags
Description: Developmental Red flags Questionnaires
Study NCT01925703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium ferric gluconate
Description: Sodium ferric gluconate 250 mg administered intravenously every 12 hours until iron repletion completed (as determined by Ganzoni equation) or patient discharge, whichever comes first.
Study NCT03062501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Patients hospitalized for uncomplicated pain crisis with a pain scale of ≥ 6 during the last 24 hours will receive a dose of 30-40 mg / kg hydroxyurea. This same dose of hydroxyurea will be repeated at 24 h and 48 h after the first dose of hydroxyurea, with dose suspension if the patient is discharged within 48 hours. Patients will also receive the center's usual practice and analgesia protocol.
Study NCT03431012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Agency Assignment framing
Description: Linguistic framing used in written health messages. Each version of the messages described the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to either humans (HA: 'You can contract the virus when you touch...') or the pandemic flu virus itself (VA: 'It can infect you when you touch...')
Study NCT03431012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attribute framing
Description: Linguistic framing used in written health messages. Each message described the side effects of the antivirals in terms of chances of either experiencing (negative framing: 'Uncommon side effects (10% of people will be affected)') or not experiencing side effects (positive framing: 'Uncommon side effects (90% of people will not be affected)') after using them.
Study NCT01823263 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intake task
Description: After a normal night of sleep or partial sleep deprivation, participants are presented with an ad libitum meal choice and can select the amount to ingest during a limited time window. Amount and selection will be recorded
Study NCT01823263 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working memory function task
Description: Participants will be evaluated on their working memory performance in the morning following either nighttime intervention (NS or PSD)
Study NCT04437199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tricaprilin
Description: Powder formulation will be mixed with 240 mL water and shaken until fully dispersed.~Each dosing unit of 12.5 g of AC-SD-03 contains 5 g of the active ingredients (tricaprilin)
Study NCT04437199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Powder formulation will be mixed with 240 mL water and shaken until fully dispersed.
Study NCT00906399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB017 (peginterferon beta-1a)
Description: Supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 µg dose), self-administered by subcutaneous injection.
Study NCT00906399 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BIIB017 (peginterferon beta-1a)
Description: Supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 µg dose), self-administered by subcutaneous injection.
Study NCT00906399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo provided in pre-filled syringes, to deliver 0.5 mL self-administered by subcutaneous injection.
Study NCT00906399 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo provided in pre-filled syringes, to deliver 0.5 mL self-administered by subcutaneous injection.
Study NCT01429870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid active treatment
Description: Triamcinolone in unguentum leniens 0.1%
Study NCT01429870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Steroid active treatment
Description: Triamcinolone in unguentum leniens 0.1%
Study NCT03490058 — intervention group
Intervention type: DRUG
Intervention: Truvada
Description: A fixed dose of oral co-formulated tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) will be used as PrEP.